Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)

NCT01863186 is registered in ClinicalTrials.gov with USWM, LLC (dba US WorldMeds) as lead sponsor.

NCT NCT01863186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01863186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Lead sponsor
USWM, LLC (dba US WorldMeds)
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2013
Completion date
December 31, 2014
Enrollment
603 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute opioid withdrawal syndrome, opioid dependence